title: Serum chromogranin A reflects regression of metastatic   carcinoid during prolonged octreotide treatment.
authors.affiliation: 2nd Department of Medicine, Semmelweis University, Budapest, Hungary. pregunistvan@yahoo.com
authors.forename: Istvan
authors.initials: I
authors.lastname: Pregun
authors.forename: Peter
authors.initials: P
authors.lastname: Gergics
authors.forename: Gabriella
authors.initials: G
authors.lastname: Dabasi
authors.forename: Peter
authors.initials: P
authors.lastname: Igaz
authors.forename: Karoly
authors.initials: K
authors.lastname: Racz
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Tulassay
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D002276:Carcinoid Tumor / Q000188:drug therapy / Q000556:secondary*; D053379:Chromogranin A / Q000097:blood*; D005260:Female; D005757:Gastritis, Atrophic / Q000097:blood; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000097:blood
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D053379:Chromogranin A; D015282:Octreotide